Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? - Madrid 2019

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

International Congresses Madrid 2019

Novel molecular pathways in lung cancer and COPD

Chair(s): P. Bonniaud (Dijon, France), E. Garrido-Martin (Madrid, Spain)

Session type: Oral Presentation

Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma?

Y. Badi (London, United Kingdom), A. Pavel (New York, United States of America), J. Riley (Stevenage, United Kingdom), K. Chung (London, United Kingdom), E. Guttman-Yassky (New York, United States of America), I. Adcock (London, United Kingdom)

EVENTS HOME

Limited Access

Please log in to myERS to view this content.

Don't have a myERS account? Register

Note: consult the ERS Respiratory Channel access rights page for more details.

CDN Connection Issue

The ERS International Congress 2019, Madrid

Limited Access

#{title}